<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04116073</url>
  </required_header>
  <id_info>
    <org_study_id>J19106</org_study_id>
    <secondary_id>IRB00224849</secondary_id>
    <nct_id>NCT04116073</nct_id>
  </id_info>
  <brief_title>INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic Cancer</brief_title>
  <official_title>A Phase II Trial of INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2 study to evaluate the clinical activity of INCMGA00012 in patients with Unresectable
      or metastatic Adenosquamous Pancreatic Cancer (ASQ).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2020</start_date>
  <completion_date type="Anticipated">August 2028</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Control Rate (DCR) at 4 months using RECIST 1.1</measure>
    <time_frame>4 months</time_frame>
    <description>DCR at 4 months following the start of treatment with INCMGA00012, which is defined as the proportion of subjects with PR or CR or stable disease according to RECIST 1.1 following 4 months from the start of therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with partial response (PR) or complete response (CR)</measure>
    <time_frame>4 years</time_frame>
    <description>Number of subjects with partial response (PR) or complete response (CR) according to RECIST 1.1 will be used to assess Objective response rate (ORR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of months from the first dose of INCMGA00012 to disease progression (PD) or relapse from complete response</measure>
    <time_frame>4 years</time_frame>
    <description>Number of months from the first dose of INCMGA00012 to disease progression (PD) or relapse from complete response (CR) as assessed using RECIST 1.1 or death. This will be used in assessing Progression-free survival (PFS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing study drug-related toxicities</measure>
    <time_frame>4 years</time_frame>
    <description>Number of participants experiencing study drug-related adverse events Grade 3 or higher as defined by CTCAE v5.0.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Pancreatic Cancer Non-resectable</condition>
  <condition>Pancreatic Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>INCMGA00012 (PD-1 antibody)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive the interventional study drug; INCMGA00012.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCMGA00012 (PD-1 antibody)</intervention_name>
    <description>Treatment of INCMGA00012 will be administered every 4 weeks (28 days) while patient is on study. Intravenous administration of INCMGA00012 (500 mg) will occur on Day 1 of each 28 day cycle.
Drug: 500 mg is to be administered as a 30 minute IV infusion (-5/+15 min)</description>
    <arm_group_label>INCMGA00012 (PD-1 antibody)</arm_group_label>
    <other_name>MGA012</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years.

          -  Have histologically or cytologically - proven adenosquamous carcinoma of the pancreas.

          -  Has unresectable or metastatic measurable disease.

          -  Has received (or been intolerant to or ineligible for) at least 1 prior line of
             cytotoxic chemotherapy and received no more than 2 prior systemic treatments.

          -  Presence of at least one lesion with measurable disease.

          -  Accept to have a tumor biopsy of an accessible lesion at baseline and on treatment.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

          -  If HIV-positive, then all of the following criteria must also be met: cluster of
             differentiation (CD) 4+ count ≥ 350/μL, undetectable viral load, and receiving highly
             active antiretroviral therapy.

          -  Life expectancy of greater than 3 months.

          -  Patients must have adequate organ and marrow function defined by study-specified
             laboratory tests prior to initial study drug.

          -  Woman of childbearing potential must have a negative pregnancy test and follow
             contraceptive guidelines as defined per protocol.

          -  Men must use acceptable form of birth control while on study.

          -  Ability to understand and willingness to sign a written informed consent document.

        Exclusion Criteria

          -  Known history or evidence of brain metastases.

          -  Has had chemotherapy, radiation, or biological cancer therapy within 14 days prior to
             the first dose of study drug.

          -  Has received an investigational agent or used an investigational device within 28 days
             of the first dose of study drug.

          -  Expected to require any other form of systemic or localized antineoplastic therapy
             while on study.

          -  Has had major surgery within 28 days of dosing of investigational agent, excluding
             minor procedures.

          -  Has received a live vaccine within 28 days prior to the first dose of study drug.

          -  Prior treatment with immunotherapy agents (including, anti-PD-1, anti-PD-L1,
             anti-PD-L2, anti-CTLA4, anti-OX40 and LAG-3 antibodies)

          -  Have used any systemic steroids within 14 days of study treatment.

          -  Hypersensitivity reaction to any monoclonal antibody.

          -  Evidence of clinical or radiographic ascites.

          -  Have clinically significant and/or malignant pleural effusion.

          -  Uncontrolled intercurrent illness including, but not limited to, uncontrolled
             infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia,
             metastatic cancer, or psychiatric illness/social situations that would limit
             compliance with study requirements.

          -  History of autoimmune disease requiring systemic immunosuppression within the last 2
             years.

          -  Presence of any tissue or organ allograft, regardless of need for immunosuppression,
             including corneal allograft. Patients with a history of allogeneic hematopoeitic stem
             cell transplant will be excluded.

          -  All toxicities attributed to prior anti-cancer therapy other than alopecia and fatigue
             must have resolved to a grade 1 or baseline before administration of study drug.

          -  Infection with Hepatitis A, B or C.

          -  Patient has a pulse oximetry of &lt;92% on room air.

          -  Patient is on supplemental home oxygen.

          -  Has an unhealed surgical wound or ulcer, or a bone fracture considered non-healing.

          -  Patient has clinically significant heart disease.

          -  Patient is, at the time of signing informed consent, a regular user (including
             &quot;recreational use&quot;) of any illicit drugs or other substance abuse.

          -  Unwilling or unable to follow the study schedule for any reason.

          -  Patient has history of non-infectious pneumonitis.

          -  Serum albumin level less than 2.8 g/dL.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nilofer Azad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Medical Institution</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan Sartorius-Mergenthaler, RN</last_name>
    <phone>410-614-3644</phone>
    <email>Sartosu@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ellen Lilly-Foreman, RN</last_name>
    <phone>443-287-4961</phone>
    <email>lillyel@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Sartorius-Mergenthaler, RN</last_name>
      <phone>410-614-3644</phone>
      <email>Sartosu@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ellen Foreman-Lilly, RN</last_name>
      <phone>443-287-4961</phone>
      <email>lillyel@jhmi.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 3, 2019</study_first_submitted>
  <study_first_submitted_qc>October 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2019</study_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antibody</keyword>
  <keyword>Anti-PD-1</keyword>
  <keyword>Human monoclonal immunoglobulin antibody</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>INCMGA00012 (anti-PD-1 antibody)</keyword>
  <keyword>Anti-PD-1 antibody (MGA012)</keyword>
  <keyword>Metastatic adenosquamous pancreatic cancer</keyword>
  <keyword>Unresectable adenosquamous pancreatic cancer</keyword>
  <keyword>Adenosquamous pancreatic cancer</keyword>
  <keyword>Programmed cell death protein 1 (PD-1)</keyword>
  <keyword>Programmed death-ligand 1 (PD-L1)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

